Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
BioAtla ( (BCAB) ) has provided an announcement.
On May 12, 2025, BioAtla, Inc. received a notice from Nasdaq indicating non-compliance with the $10 million minimum stockholders’ equity requirement, as their equity was reported at $547,000 as of March 31, 2025. This notice does not immediately affect BioAtla’s Nasdaq listing, and the company has until June 26, 2025, to submit a compliance plan. If accepted, Nasdaq may grant a 180-day extension. BioAtla plans to submit the plan and take necessary measures to regain compliance, although there is no assurance of approval or eventual compliance.
The most recent analyst rating on (BCAB) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on BioAtla stock, see the BCAB Stock Forecast page.
Spark’s Take on BCAB Stock
According to Spark, TipRanks’ AI Analyst, BCAB is a Underperform.
BioAtla’s stock faces significant challenges, primarily due to its financial position, characterized by a lack of revenue and high cash burn. Despite promising clinical progress and strategic efforts to manage cash, the company’s valuation and technical indicators reflect a bearish outlook. The overall score reflects these substantial risks, with some potential upside from clinical developments.
To see Spark’s full report on BCAB stock, click here.
More about BioAtla
BioAtla, Inc. operates in the biotechnology industry, focusing on the development of conditionally active biologics (CABs) for the treatment of various cancers. The company is dedicated to advancing innovative therapies that target specific cancer cells while minimizing damage to healthy tissues.
Average Trading Volume: 657,207
Technical Sentiment Signal: Sell
Current Market Cap: $23.92M
Find detailed analytics on BCAB stock on TipRanks’ Stock Analysis page.